U.S. Markets closed

CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal Study

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • CureVac BV (NASDAQ: CVAC) has announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GlaxoSmithKline Plc (NYSE: GSK), in the journal Nature.

  • Related Link: CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study.

  • The newly published data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 shot, Comirnaty.

  • Neutralizing antibody levels measured following complete vaccination of animals with either 12µg of CV2CoV or a 30µg standard dose of Comirnaty were shown to be highly comparable.

  • The data confirm how targeted optimizations of a non-chemically modified mRNA can significantly improve immune responses in a preclinical model.

  • Also Read: CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans.

  • Price Action: CVAC shares are up 4.43% at $41.43 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.